Switching to an integrase inhibitor can raise diabetes risk in people with HIV
The untapped potential of CD8 cells
Bictegravir/lenacapavir combination pill could be an option for people taking complex regimens
Hepatitis B reactivation is rare after switching from tenofovir, two European studies show
Treatment changes do not reduce weight in people with HIV
Dolutegravir resistance very rare after a switch - even with detectable HIV
Switching from TAF to TDF leads to weight loss
Increasing and changing pattern of treatment switches among people with HIV
Reduced-drug treatment becoming common in Paris
